We are live on ! Find out more
MTCR

Metacrine, Inc. Common Stock
MTCR

Delisted

MTCR was delisted on the 8th of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Metacrine, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $5.3M → $0 (-$5.3M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
–
Holders Change
-5
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$3.52M
2
JC
JBF Capital
Colorado
-$1.11M
3
AG
Artal Group
Luxembourg
-$528K
4
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$136K
5
WS
Wedbush Securities
California
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
– -$3.52M -6,167,458 Closed
JC
2
JBF Capital
Colorado
– -$1.11M -1,945,270 Closed
AG
3
Artal Group
Luxembourg
– -$528K -924,898 Closed
Tudor Investment Corp
4
Tudor Investment Corp
Connecticut
– -$136K -239,100 Closed
WS
5
Wedbush Securities
California
– -$7K -12,700 Closed

MTCR Hedge Fund Activity: Q2 2023 in Review

0 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q2 2023, worth a combined $0 — down 100% from $5.3M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MTCR and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BML Capital Management, exiting entirely with an estimated $3.52M sold.

  • 0 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q2 2023, down from 5 in Q1 2023.
  • Funds reported $0 of Metacrine, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Metacrine, Inc. Common Stock positions in Q2 2023 and 5 closed out, a net change of -5 holders.
  • The largest Metacrine, Inc. Common Stock seller in Q2 2023 was BML Capital Management, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2023.